ir.moleculin.com

Moleculin Biotech, Inc. (MBRX)

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Our lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. We also have two active pre-clinical small molecule portfolios, one of which is focused on the modulation of ha

http://ir.moleculin.com/

OVERVIEW OF ir.moleculin.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

10

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR IR.MOLECULIN.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

March

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Tuesday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 3.7 out of 5 with 14 reviews

5 star

5

4 star

4

3 star

3

2 star

0

1 star

2

Hey there! Start your review of ir.moleculin.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

0.4 seconds

CONTACTS AT IR.MOLECULIN.COM

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

PAGES IN
THIS WEBSITE

10

SSL

EXTERNAL LINKS

21

SITE IP

52.8.221.80

LOAD TIME

0.359 sec

SCORE

6.2

PAGE TITLE

Moleculin Biotech, Inc. (MBRX) | ir.moleculin.com Reviews

<META> DESCRIPTION

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Our lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. We also have two active pre-clinical small molecule portfolios, one of which is focused on the modulation of ha

<META> KEYWORDS

1 children

2 technology

3 annamycin

4 about aml

5 about ctcl

6 about brain tumors

7 cardiotoxicity

8 multidrug resistance

9 development pipeline

10 investors

CONTENT

Page content here

KEYWORDS ON PAGE

children,technology,annamycin,about aml,about ctcl,about brain tumors,cardiotoxicity,multidrug resistance,development pipeline,investors,overview,news / events,company information,financial information,stock data,sec filings,corporate governance,about us

SERVER

Apache

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Moleculin Biotech, Inc. (MBRX) | ir.moleculin.com Reviews

https://ir.moleculin.com

Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company focused on the development of anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Our lead product candidate is Annamycin, a Phase II clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML. We also have two active pre-clinical small molecule portfolios, one of which is focused on the modulation of ha

INTERNAL PAGES

ir.moleculin.com

1

Email Alerts :: Moleculin Biotech, Inc. (MBRX)

http://ir.moleculin.com/email-alerts

Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology. Annamycin vs. Daunorubicin. Management & Business Advisors. Partnerships & Collaborations. Please fill out the form below to receive company press releases via email when they occur.

2

News / Events :: Moleculin Biotech, Inc. (MBRX)

http://ir.moleculin.com/news-events

Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology. Annamycin vs. Daunorubicin. Management & Business Advisors. Partnerships & Collaborations. 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. November 30, 2016.

3

All SEC Filings :: Moleculin Biotech, Inc. (MBRX)

http://ir.moleculin.com/all-sec-filings

Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology. Annamycin vs. Daunorubicin. Management & Business Advisors. Partnerships & Collaborations. Prospectus filed pursuant to Rule 424(b)(4).

4

Company Information :: Moleculin Biotech, Inc. (MBRX)

http://ir.moleculin.com/company-information

Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology. Annamycin vs. Daunorubicin. Management & Business Advisors. Partnerships & Collaborations. Answers to commonly asked questions. Kirin M. Smith. VStock Transfer, LLC.

5

Stock Data :: Moleculin Biotech, Inc. (MBRX)

http://ir.moleculin.com/stock-data

Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology. Annamycin vs. Daunorubicin. Management & Business Advisors. Partnerships & Collaborations. Moleculin Biotech, Inc.

UPGRADE TO PREMIUM TO VIEW 5 MORE

TOTAL PAGES IN THIS WEBSITE

10

LINKS TO THIS WEBSITE

moleculin.com

Partnerships & Collaborations - Moleculin Biotech

http://www.moleculin.com/about-moleculin/partnerships

Moleculin Biotech, Inc. is a pre-clinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology. Annamycin vs. Daunorubicin. Management & Business Advisors. Partnerships & Collaborations. Partnerships & Collaborations. Partnerships & Collaborations. DERMIN SP. ZO. O.

moleculin.com

Board of Directors - Moleculin Biotech

http://www.moleculin.com/about-moleculin/board-of-directors

Moleculin Biotech, Inc. is a pre-clinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology. Annamycin vs. Daunorubicin. Management & Business Advisors. Partnerships & Collaborations. Robert E. George. Michael D. Cannon. Management & Business Advisors. Click Here To Subscribe.

moleculin.com

Overview - Moleculin Biotech

http://www.moleculin.com/product-candidates/overview

Moleculin Biotech, Inc. is a pre-clinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology. Annamycin vs. Daunorubicin. Management & Business Advisors. Partnerships & Collaborations. Annamycin is an anthracyline intended for the treatment of relapsed or refractory acute myel...

UPGRADE TO PREMIUM TO VIEW 18 MORE

TOTAL LINKS TO THIS WEBSITE

21

SOCIAL ENGAGEMENT

moleculin

moleculinbio

OTHER SITES

ir.mobi

ir.mobi is a Premium Name

Irmobi is a Premium Name. DotMobi is collecting expressions of interest in its Premium Names. At a future date, dotMobi will allocate these domains through the most appropriate option available and any plans will be announced in advance. To express your interest for ir.mobi. And be notified when it will be made available, please complete the form below (dotMobi will not make this information available to any third parties). Please check the required fields. News from Blog.mobi.

ir.mobimo.ch

Mobimo Holding AG - Porträt

Die Mobimo Holding AG besitzt folgende Beteiligungen. BSS&M Real Estate AG. FM Service and Dienstleistungs AG. Immobilien Invest Holding AG. LO Holding Lausanne-Ouchy SA. Mobimo Zürich Nord AG. Parking du Centre SA. Die Stimmanteile betragen 5%. Seestrasse 59 8700 Küsnacht Tel. 41 44 397 11 11.

ir.mocon.com

MOCON Inc. - Investor Relations

Quarterly and Annual Reports. Consulting and Testing Services. Aroma and Flavor Testing. CGMP Permeation Test Services. Standard Permeation Rate Testing. All Consulting and Testing Services. Don’t See Your Industry? MOCON Helps a Range of Industries. Quarterly and Annual Reports. Consulting and Testing Services. Aroma and Flavor Testing. CGMP Permeation Test Services. Standard Permeation Rate Testing. All Consulting and Testing Services. Minimum 20 minute delay. August 14, 2015. Past Events and Webcasts.

ir.mofcom.gov.cn

中华人民共和国驻伊朗伊斯兰共和国大使馆经济商务参赞处

伊朗印象之美丽的大布里士风光- - - -伊朗剪影二十九. 伊朗印象之美丽的大布里士风光- - - -伊朗剪影二十八. 伊朗印象之气势雄伟的亚兹德清真寺- - - -伊朗剪影二十七. 伊朗印象之迷人的伊斯法罕- - - -伊朗剪影二十六. 伊朗印象之迷人的伊斯法罕- - - -伊朗剪影二十五. 2014年伊朗矿业及矿山机械博览会 MINEX 2014 将于10月14日开幕.

ir.mol.com

MOL - Investor Relations - Investor Home

Call Us: (603) 2082 1251. Stock Quote and Chart. Q2 2015 MOL Global Inc Earnings Conference Call. 160;at 8:00 am ET. Q2 2015 MOL Global Inc Earnings Conference Call. Friday, August 21, 2015 . 8:00 am ET . Through Friday, August 21, 2015 . Click here for webcast. Click here to add this event to your calendar. Q1 2015 MOL Global Inc Earnings Conference Call. MOL Global Inc First Quarter 2015 Financial Results. MOL Global Inc. to Announce Second Quarter 2015 Financial Results. 08/21/15 9:00 am ET. This cal...

ir.moleculin.com

Moleculin Biotech, Inc. (MBRX)

Moleculin Biotech, Inc. is preclinical and clinical-stage pharmaceutical company focused on the development of game-changing anti-cancer drug candidates, many of which are based on discoveries made at M.D. Anderson Cancer Center. Each of our projects represents a breakthrough discovery and a highly disruptive technology. Annamycin vs. Daunorubicin. Management & Business Advisors. Partnerships & Collaborations. Dec 13, 2016. Quarter Ended Sep 30, 2016. Kirin M. Smith. VStock Transfer, LLC.

ir.moliyo.com

moliyo.com

邮箱: eName24@gmail.com QQ: 9596533.

ir.momentapharma.com

Investors | Momenta Pharmaceuticals

Skip to main navigation. Email and News Alerts. Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilars and to the discovery and development of novel therapeutics for autoimmune indications. 20 mg/mL (glatiramer acetate injection), a fully substitutable generic version of COPAXONE. Mar 29, 2018. Momenta ...

ir.monashivfgroup.com.au

Monash IVF Group - Investor Centre

Monash Ultrasound for Women. Announcements and Media Releases. Share Price and Tools. Share Price and Graphs. Announcements and Media Releases. Share Price and Tools. Share Price and Graphs. As at 4:00PM 18/08/2015. About Monash IVF Group. Monash Ultrasound for Women. Share Price and Tools. 2014 Monash IVF Group.

ir.monolithicpower.com

Investor Relations | Monolithic Power Systems, Inc.

Skip to main navigation. AC/DC and LED Lighting Reference Designs. FPGA and SoC Reference Designs. Position Sensors Design Support. FPGA and SoC Reference Designs. AC/DC and LED Lighting Reference Designs. Quality Policy, Programs and Certificates. Reliability Programs and Reports. Environmental Certification and Reports. MPS Offices and Partners. Signup for Email Alerts. News and Press Release. Annual Reports and Proxies. Mar 27, 2018. Feb 8, 2018. View all financial press releases.

ir.monotype.com

Monotype - Provider of typefaces, technology and expertise

Investor br Relations span LayoutHomePageLayout Languageen-CA". Meet Our Type Design Team. Solutions for Specific Markets. Branding and Design Agencies. Fonts and Design Services. IType, iType Connect. WorldType Layout Engine, WorldType Shaper. Type Enhancements for Android. Web Fonts Extensions for Photoshop. Learn more about our company. 500 Unicorn Park Drive. Woburn, MA 01801. 800) 424-8973, prompt 2. US and Canada Only). Stock Quote and Chart. Faces, as well newer favorites such as the Ayita. Monoty...